At the time of writing, AIM ImmunoTech Inc [AIM] stock is trading at $1.51, down -4.85%. An important factor to consider is whether the stock is rising or falling in short-term value. The AIM shares have gain 13.53% over the last week, with a monthly amount drifted -40.55%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
For the past year, the stock price of AIM ImmunoTech Inc fluctuated between $1.26 and $36.00. AIM ImmunoTech Inc [AMEX: AIM] shares were valued at $1.51 at the most recent close of the market.
Analyzing the AIM fundamentals
According to AIM ImmunoTech Inc [AMEX:AIM], the company’s sales were 0.11M for trailing twelve months, which represents an -25.71% plunge. Gross Profit Margin for this corporation currently stands at 0.19% with Operating Profit Margin at -129.33%, Pretax Profit Margin comes in at -140.62%, and Net Profit Margin reading is -140.62%. To continue investigating profitability, this company’s Return on Assets is posted at -2.87, Equity is 3.54 and Total Capital is -9.98. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-0.38.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.4578 points at the first support level, and at 1.4055 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.6075, and for the 2nd resistance point, it is at 1.7049.
Ratios To Look Out For
It is important to note that AIM ImmunoTech Inc [AMEX:AIM] has a current ratio of 0.64. On the other hand, the Quick Ratio is 0.64, and the Cash Ratio is 0.58. Considering the valuation of this stock, the price to sales ratio is 39.18.
Transactions by insiders
Recent insider trading involved Equels Thomas K, CEO & President, that happened on Apr 04 ’25 when 41000.0 shares were purchased. COO, Secretary, Gen. Counsel, Rodino Peter W III completed a deal on Apr 04 ’25 to buy 500.0 shares. Meanwhile, CEO & President Equels Thomas K bought 50000.0 shares on Mar 05 ’25.
